Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47.
SGN-CD47M 的临床前开发：蛋白酶激活抗体技术可选择性地靶向先天免疫检查点受体 CD47 的肿瘤
期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-24-0371
Levengood Matthew R, Carosino Christopher M, Zhang Xinqun, Lucas Sasha, Ortiz David J, Westendorf Lori, Chin Alice P, Martin Arlan D, Wong Abbie, Hengel Shawna M, Sun Hao, Zeng Weiping, Yumul Roma, Dominguez Melissa M C, Chen Yufei, Zheng Janet H, Karlsson Courtney A B, Trang Vivian H, Senter Peter D, Gardai Shyra J
